Status

NOT RECRUITING

Purpose

PSSc-001 (LOTUSS) This study is a Phase 2, multinational, open-label, randomized, parallel-group, safety and tolerability study of pirfenidone in participants with systemic sclerosis−related interstitial lung disease (SSc-ILD).

Investigator(s)

Lorinda Chung MD MS
Rheumatologist, Immunologist
Professor of Medicine (Immunology and Rheumatology) at the Palo Alto Veterans Affairs Health Care Center

Contact us to find out if this trial is right for you.

CONTACT

SPECTRUM